CN117143176A - 降解sos1蛋白的化合物及其用途 - Google Patents
降解sos1蛋白的化合物及其用途 Download PDFInfo
- Publication number
- CN117143176A CN117143176A CN202311099847.5A CN202311099847A CN117143176A CN 117143176 A CN117143176 A CN 117143176A CN 202311099847 A CN202311099847 A CN 202311099847A CN 117143176 A CN117143176 A CN 117143176A
- Authority
- CN
- China
- Prior art keywords
- substituted
- branched
- unsubstituted
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 58
- 108700022176 SOS1 Proteins 0.000 title claims abstract description 35
- 102000057028 SOS1 Human genes 0.000 title claims abstract description 35
- 230000000593 degrading effect Effects 0.000 title claims description 6
- 230000000694 effects Effects 0.000 claims abstract description 11
- 239000003446 ligand Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 22
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 claims description 19
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 claims description 19
- 101150100839 Sos1 gene Proteins 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 239000002207 metabolite Substances 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 10
- 239000000651 prodrug Substances 0.000 claims description 10
- 239000013078 crystal Substances 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
- 125000006728 (C1-C6) alkynyl group Chemical group 0.000 claims description 5
- 125000003368 amide group Chemical group 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 125000004185 ester group Chemical group 0.000 claims description 5
- 125000000468 ketone group Chemical group 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000001276 rectum malignant melanoma Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract description 14
- 238000006731 degradation reaction Methods 0.000 abstract description 14
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 abstract description 4
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 abstract description 4
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 238000000338 in vitro Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 230000034512 ubiquitination Effects 0.000 abstract description 2
- -1 H-Ras Proteins 0.000 description 41
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 29
- 230000015572 biosynthetic process Effects 0.000 description 28
- 238000003786 synthesis reaction Methods 0.000 description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
- 108010014186 ras Proteins Proteins 0.000 description 23
- 102000016914 ras Proteins Human genes 0.000 description 23
- 239000012043 crude product Substances 0.000 description 16
- RVZPDKXEHIRFPM-UHFFFAOYSA-N tert-butyl n-(6-aminohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCCCCN RVZPDKXEHIRFPM-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 229940125904 compound 1 Drugs 0.000 description 11
- 238000001035 drying Methods 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- HJENAZQPOGVAEK-UHFFFAOYSA-N 7-[(2-methylpropan-2-yl)oxycarbonylamino]heptanoic acid Chemical compound CC(C)(C)OC(=O)NCCCCCCC(O)=O HJENAZQPOGVAEK-UHFFFAOYSA-N 0.000 description 10
- 238000003818 flash chromatography Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- VLJNHYLEOZPXFW-UHFFFAOYSA-N pyrrolidine-2-carboxamide Chemical compound NC(=O)C1CCCN1 VLJNHYLEOZPXFW-UHFFFAOYSA-N 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 125000001544 thienyl group Chemical group 0.000 description 7
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000005496 eutectics Effects 0.000 description 5
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 231100000590 oncogenic Toxicity 0.000 description 4
- 230000002246 oncogenic effect Effects 0.000 description 4
- 125000004430 oxygen atom Chemical group O* 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- 125000004434 sulfur atom Chemical group 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 3
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 3
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- BTKYLHCVXRGFLC-UHFFFAOYSA-N tert-butyl n-(11-aminoundecyl)carbamate Chemical group CC(C)(C)OC(=O)NCCCCCCCCCCCN BTKYLHCVXRGFLC-UHFFFAOYSA-N 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QMHIMXFNBOYPND-UHFFFAOYSA-N 4MTO Natural products CC1=CSC=N1 QMHIMXFNBOYPND-UHFFFAOYSA-N 0.000 description 2
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QCCWTNAQYOOPQP-UHFFFAOYSA-N 9-[(2-methylpropan-2-yl)oxycarbonylamino]nonanoic acid Chemical group CC(C)(C)OC(=O)NCCCCCCCCC(O)=O QCCWTNAQYOOPQP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- WEGLOYDTDILXDA-OAHLLOKOSA-N CNCc1ccccc1-c1csc(c1)[C@@H](C)Nc1nc(C)nc2cc(OC)c(OC)cc12 Chemical compound CNCc1ccccc1-c1csc(c1)[C@@H](C)Nc1nc(C)nc2cc(OC)c(OC)cc12 WEGLOYDTDILXDA-OAHLLOKOSA-N 0.000 description 2
- 101710113436 GTPase KRas Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RSAPJHYIFKJREV-UHFFFAOYSA-N tert-butyl n-(10-aminodecyl)carbamate Chemical group CC(C)(C)OC(=O)NCCCCCCCCCCN RSAPJHYIFKJREV-UHFFFAOYSA-N 0.000 description 2
- DTJYPERGUPPXRU-UHFFFAOYSA-N tert-butyl n-(7-aminoheptyl)carbamate Chemical group CC(C)(C)OC(=O)NCCCCCCCN DTJYPERGUPPXRU-UHFFFAOYSA-N 0.000 description 2
- GZUNGYDAMPRXSU-UHFFFAOYSA-N tert-butyl n-(9-aminononyl)carbamate Chemical group CC(C)(C)OC(=O)NCCCCCCCCCN GZUNGYDAMPRXSU-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- JWOHBPPVVDQMKB-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-carboxylic acid Chemical group CC(C)(C)OC(=O)N1CCC(C(O)=O)CC1 JWOHBPPVVDQMKB-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- JAPYIBBSTJFDAK-UHFFFAOYSA-N 2,4,6-tri(propan-2-yl)benzenesulfonyl chloride Chemical compound CC(C)C1=CC(C(C)C)=C(S(Cl)(=O)=O)C(C(C)C)=C1 JAPYIBBSTJFDAK-UHFFFAOYSA-N 0.000 description 1
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile Chemical compound ClC=1C=CC=C2C=CC=C(C=12)N1CC=2N=C(N=C(C=2CC1)N1C[C@@H](N(CC1)C(C(=C)F)=O)CC#N)OC[C@H]1N(CCC1)C PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- 125000005925 3-methylpentyloxy group Chemical group 0.000 description 1
- DPBWFNDFMCCGGJ-UHFFFAOYSA-N 4-Piperidine carboxamide Chemical compound NC(=O)C1CCNCC1 DPBWFNDFMCCGGJ-UHFFFAOYSA-N 0.000 description 1
- BEDWYXZFIYMEJG-UHFFFAOYSA-N 4-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]benzoic acid Chemical group C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(C(O)=O)C=C1 BEDWYXZFIYMEJG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- FQTFIMUPUQFJFK-UHFFFAOYSA-N 6,7-dimethoxy-2-methylquinazoline Chemical compound N1=C(C)N=C2C=C(OC)C(OC)=CC2=C1 FQTFIMUPUQFJFK-UHFFFAOYSA-N 0.000 description 1
- RUFDYIJGNPVTAY-UHFFFAOYSA-N 6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical group CC(C)(C)OC(=O)NCCCCCC(O)=O RUFDYIJGNPVTAY-UHFFFAOYSA-N 0.000 description 1
- FPRZYWCRQHFPSX-UHFFFAOYSA-N 8-[(2-methylpropan-2-yl)oxycarbonylamino]octanoic acid Chemical group CC(C)(C)OC(=O)NCCCCCCCC(O)=O FPRZYWCRQHFPSX-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 229940125795 BI-3406 Drugs 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- 101100421901 Caenorhabditis elegans sos-1 gene Proteins 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101000868154 Homo sapiens Son of sevenless homolog 2 Proteins 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100032930 Son of sevenless homolog 2 Human genes 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- AFHOBSCDNXGFMO-UHFFFAOYSA-N [2-(hydroxymethyl)phenyl]boronic acid Chemical compound OCC1=CC=CC=C1B(O)O AFHOBSCDNXGFMO-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229940124988 adagrasib Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical group C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102200006538 rs121913530 Human genes 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ZFSCBYAYUUFEPJ-UHFFFAOYSA-N tert-butyl n-(12-aminododecyl)carbamate Chemical group CC(C)(C)OC(=O)NCCCCCCCCCCCCN ZFSCBYAYUUFEPJ-UHFFFAOYSA-N 0.000 description 1
- RQRMFFGCUUGYPC-UHFFFAOYSA-N tert-butyl n-(2-piperidin-4-ylethyl)carbamate Chemical group CC(C)(C)OC(=O)NCCC1CCNCC1 RQRMFFGCUUGYPC-UHFFFAOYSA-N 0.000 description 1
- IOKGWQZQCNXXLD-UHFFFAOYSA-N tert-butyl n-(3-bromopropyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCCBr IOKGWQZQCNXXLD-UHFFFAOYSA-N 0.000 description 1
- BEHVGNKIRNVBPF-UHFFFAOYSA-N tert-butyl n-(8-aminooctyl)carbamate Chemical group CC(C)(C)OC(=O)NCCCCCCCCN BEHVGNKIRNVBPF-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本发明属于药物化学技术领域,尤其涉及靶向SOS1蛋白泛素化调节的双官能团化合物及其制备方法和应用。所述化合物为E3连接酶配体、SOS1蛋白配体,任选还包括连接子结构三部分组成,经体外活性测试证明其对SOS1蛋白具有良好的降解能力。
Description
技术领域
本发明属于药物化学技术领域,尤其涉及靶向SOS1蛋白泛素化调节的双官能团化合物及其制备方法和应用。
背景技术
Ras蛋白(包括H-Ras、N-Ras、K-Ras)属于小GTP酶超家族,是多条细胞信号通路中的重要节点,与细胞的增殖、分化密切相关。Ras蛋白发挥作用取决于其GTP结合状态,即GTP结合的活性状态与GDP结合的非活性状态。这种两种状态受GTP酶活化蛋白(GAPs)和鸟苷酸交换因子(GEFs)调控。通过在两种状态之间转化,Ras在信号通路中发挥“开关”作用,实现信号的转导。Ras蛋白本身具有较弱的GTP酶水解活性,该活性可以被GAPs增强,促进GTP水解为GDP,使Ras蛋白转化为失活状态;GEFs则可催化Ras蛋白释放GDP,从而与细胞内浓度更高的GTP结合,使Ras蛋白转化为失活状态。
Ras蛋白的激活突变是人类癌症中最常见的致癌驱动因素之一,尤其以K-Ras突变为主,约占Ras突变的75%,涉及胰腺癌、结直肠癌、肺腺癌等多种癌症。Ras蛋白发生致癌突变后,GTP水解能力受损,使其稳定在GTP结合的活性形式,引起下游信号通路的持续激活,其最常见的突变位点是12、13、61位氨基酸。尽管Ras蛋白是许多癌症治疗的潜在研究靶点,但是由于Ras蛋白表面相对平滑,缺乏可以结合小分子化合物的口袋,因此被称为“不可成药”靶点。目前选择性靶向KRAS-G12C的共价抑制剂AMG510和MRTX849已进入临床研究阶段,然而迄今为止仍有多种突变型Ras引起的癌症无药可用。
SOS1蛋白是一种作用于Ras蛋白的GEFs,可以促进GDP与GTP的交换激活信号分子Ras。SOS1蛋白具有两个Ras结合位点,分别是与GDP-Ras结合的催化位点和GTP-Ras结合的变构位点。1值得注意的是,致癌突变的Ras通过于SOS1蛋白的变构位点结合来促进SOS1介导的野生型Ras的活化。由此可见,SOS1蛋白在Ras信号通路的激活,尤其是致癌Ras引起的信号通路过度激活中发挥十分重要的调控作用。因此通过抑制SOS1的作用达到阻断Ras相关信号通路,从而抑制肿瘤细胞增殖分化可能是治疗Ras驱动癌症的有效策略。目前已经报道的SOS1抑制剂有BAY-293和BI-3406,其中BI-3406系列化合物已经进入临床研究阶段,然而该化合物单独使用时治疗效果未达到预期目标,这可能与该信号通路的负反馈调节及SOS2的代偿作用有关,目前该化合物正在尝试联合用药的治疗策略。2
蛋白降解靶向嵌合体(PROTAC)技术是近年来新兴的药物研发策略,利用该策略设计出的蛋白靶向降解剂可以在体内发挥类似催化剂作用,通过降解致病蛋白,达到治疗疾病的目的,有着微量高效的特点,有望解决传统小分子抑制剂毒副作用大、容易产生耐药性等不足,并可作用于“不可成药”蛋白靶点,成为药物创新研究的亮点。PROTAC分子通常由三部分组成,分别是E3泛素连接酶配体、靶蛋白配体以及将两者连接的连接结构,PROTAC分子可以在体内将靶蛋白和E3泛素连接酶拉近,形成三元复合物,给靶蛋白打上泛素标签,然后通过泛素-蛋白酶体系统(UPS)降解目标蛋白。通过直接调控体内蛋白含量治疗疾病,为创新药物研究提供了广阔的新思路。
综上所述,为解决Ras相关疾病无药可用、治疗效果差的现状,本课题旨在设计合成靶向SOS1蛋白的降解剂,通过减少体内SOS1的含量达到抑制Ras相关信号通路的目的,从而抑制癌症的发展。
发明内容
本发明目的是提供一种降解SOS1蛋白的化合物,所述化合物为E3连接酶配体、SOS1蛋白配体,任选还包括连接子结构三部分组成,经体外活性测试证明其对SOS1蛋白具有良好的降解能力。
本发明提供了式I的化合物、立体异构体或其药学上可接受的盐,其结构如下所示:
其中:
X1、X2各自独立地选自N或C;
Y选自N、S、O、Si或P;
所述R9选自:H;卤素;取代或未取代的直链或支链C1-C6烷基;取代或未取代的直链或支链C1-C6氰基;取代或未取代的直链或支链C1-C6烯基;取代或未取代的直链或支链C1-C6炔基;取代或未取代的直链或支链C1-C6烷氧基;取代或未取代的直链或支链C1-C6仲胺基、叔胺基或季胺基;取代或未取代的直链或支链C1-C6酯基;取代或未取代的直链或支链C1-C6酰胺基;取代或未取代的直链或支链C1-C6酮基;取代或未取代的C1-C10环烷基;取代或未取代的C1-C10杂环基;取代或未取代的C1-C10芳基或杂芳基;
所述G基团选自取代的:
其中:
X选自N或C;
W选自S或O;
m1、m2各自独立的为0-4的整数;
所述R1选自H;-OH;-NH2;卤素;取代或未取代的直链或支链C1-C3烷基;取代或未取代的直链或支链C1-C3烯基;取代或未取代的直链或支链C1-C3炔基;取代或未取代的直链或支链C1-C3羰基;取代或未取代的C1-C10环烷基;取代或未取代的C1-C10杂环基;取代或未取代的C1-C10芳基或杂芳基;
所述连接基团2选自:不存在;或者取代或未取代的直链或具有支链的C1-C12亚烷基;任选的碳链中含有1-4个选自N、S、O、Si或P的杂原子;
所述E3配体选自:
其中:
Q选自CH2、C=O或SO2;
W1、W2、W3各自独立地选自O或S;
m为0-3的整数;
所述R2、R3、R4、R5、R6、R7和R8各自独立的选自:H;-OH;-NH2;卤素;取代或未取代的直链或支链C1-C6烷基;取代或未取代的直链或支链C1-C6氰基;取代或未取代的直链或支链C1-C6烯基;取代或未取代的直链或支链C1-C6炔基;取代或未取代的直链或支链C1-C6烷氧基;取代或未取代的直链或支链C1-C6仲胺基、叔胺基或季胺基;取代或未取代的直链或支链C1-C6酯基;取代或未取代的直链或支链C1-C6酰胺基;取代或未取代的直链或支链C1-C6酮基;取代或未取代的C1-C10环烷基;取代或未取代的C1-C10杂环基;取代或未取代的C1-C10芳基或杂芳基。
优选地,其具有式II所示的结构,
更具体地,本发明提供了一种化合物、立体异构体、或其盐,其选自如下化合物:
本发明的一些实施例涉及一种通式Ⅰ所述的化合物或其立体异构体、溶剂化合物、前药、代谢物、药学上可接受的盐或共晶。
本发明也提供所述的化合物的制备方法,其由本发明的合成路线I与合成路线II、III或IV组合制备得到所述化合物。
本发明涉及一种药物组合物,包括本发明所述的化合物或其立体异构体、溶剂化合物、前药、代谢物、药学上可接受的盐或共晶,以及药学上可接受的载体。
本发明涉及一种本发明所述的化合物或其立体异构体、溶剂化合物、前药、代谢物、药学上可接受的盐或共晶在用于制备治疗与SOS1活性或表达量相关疾病的药物中的应用。
本发明涉及一种本发明所述的化合物或其立体异构体、溶剂化合物、前药、代谢物、药学上可接受的盐或共晶在用于制备抑制SOS1活性或降低SOS1表达量的药物中的应用。
如上所述的化合物或其立体异构体、溶剂化合物、前药、代谢物、药学上可接受的盐或共晶,可作为SOS1降解剂,可用于预防和/或治疗结肠癌、非小细胞肺癌、胰腺癌、直肠癌、黑色素瘤、多发性骨髓瘤。
术语约定:
“立体异构体”是具有相同化学组成但原子或基团在空间中的排布不同的化合物。其包括“非对映异构体”和“对映异构体”
“非对映异构体”是具有两个或更多手性中心并且其分子不是彼此的镜像的立体异构体。非对映异构体具有不同物理性能,例如:熔点、沸点、谱特性和反应活性。在拆分剂或色谱存在的情况下,使用诸如手性HPLC柱,可以在诸如电泳、结晶的高分辨分析步骤下分离非对映异构体的混合物。
“对映异构体”指代彼此无重叠镜像的一种化合物的两个立体异构体。对映异构体的50:50的混合称为外消旋混合物或外消旋体,其在化学反应或处理过程中可以出现在已经没有立体选择性或立体定向性的情况下。
“烷基”包括支链和直链饱和脂肪族烃基两者,并具有指定数量的碳原子数量,一般1至约12个碳原子。如在本文中使用的术语C1-C6烷基表示具有1至约6个碳原子的烷基。当本文中结合另一基团使用C0-Cn烷基时,以(苯基)C0-C4烷基为例,指定的基团,在这种情况下,苯基是通过单个共价键(C0)直接键合或通过具有指定的碳原子数(在这种情况下,1至约4个碳原子)的烷基链连接。烷基的实例包括但不限于:甲基、乙基、正丙基、异丙基、正丁基、3-甲基丁基、叔丁基、正戊基、和仲戊基。
“烯基”或“烯烃基”指包括一个或多个不饱和的碳-碳键的直链和支链烃链,碳-碳键可以出现在沿着链的任一稳定点。本文中所述的烯基通常具有2至约12个碳原子。优选烯基是低级烯基,那些烯基具有2至约8个碳原子,如:C2-C8、C2-C6、和C2-C4烯基。烯基的实例包括乙烯基、丙烯基、和丁烯基。
“烷氧基”是指具有通过氧桥连接的指定数量的碳原子的如上所定义的烷基。烷氧基的实例包括但不限于甲氧基、乙氧基、3-己氧基、和3-甲基戊氧基。
术语“杂环”表示5-至8-元饱和环、部分不饱和环、或包含选自N、O和S的1至约4个杂原子且剩余的环原子是碳的芳族环,或是7至11元饱和环、部分不饱和环、或芳族杂环系统和10至15-元三环系统,该系统包含选自N、O和S的多环系统中的至少1个杂原子并且在多环系统中的各环中包含独立地选自N、O和S的至多约4个杂原子。除非另外指明,否则杂环可以连接至它在任何杂原子和碳原子处取代并且产生稳定结构的基团。当指明时,本文中所述的杂环可以在碳或氮原子上被取代,只要得到的化合物是稳定的。可以可选地季铵化杂环中的氮原子。优选杂环基中杂原子的总数不大于4而且优选杂环基中S和O原子的总数不大于2,更优选不大于1。杂环基的实例包括:吡啶基、吲哚基、嘧啶基、哒嗪基(pyridizinyl)、吡嗪基、咪唑基、噁唑基、呋喃基、苯硫基、噻唑基、三唑基、四唑基、异噁唑基、喹啉基、吡咯基、吡唑基、苯并[b]苯硫基(benz[b]thiophenyl)、异喹啉基、喹唑啉基、喹喔啉基、噻吩基、异吲哚基、二氢异吲哚基、5,6,7,8-四氢异喹啉、吡啶基、嘧啶基、呋喃基、噻吩基、吡咯基、吡唑基、吡咯烷基、吗啉基、哌嗪基、哌啶基、和吡咯烷基。
“芳基”或“杂芳基”表示包含选自N、O和S的1至4个、或优选1至3个杂原子并且剩余环原子为碳的稳定的5-或6-元单环或多环。当杂芳基中S和O原子的总数超过1时,这些杂原子不彼此邻近。优选杂芳基中S和O原子的总数不大于2。尤其优选杂芳基中S和O原子的总数不大于1。可以可选地季铵化杂环中的氮原子。当指明时,这些杂芳基还可以用碳或非碳原子或基团取代。这种取代可以包括与可选地包含独立地选自N、O和S的1或2个杂原子的5至7-元饱和的环基的稠合,从而形成例如[1,3]二噁唑并[4,5-c]吡啶基。杂芳基的实例包括但不限于:吡啶基、吲哚基、嘧啶基、哒嗪基、吡嗪基、咪唑基、噁唑基、呋喃基、苯硫基、噻唑基、三唑基、四唑基、异噁唑基、喹啉基、吡咯基、吡唑基、苯并[b]苯硫基、异喹啉基、喹唑啉基、喹喔啉基、噻吩基、异吲哚基、和5,6,7,8-四氢异喹啉。
“药学上可接受的盐”或“化合物的盐”是所公开的化合物的衍生物,其中,母体化合物通过制备无毒的酸或其碱加成盐。
附图说明
图1为化合物1对SOS1降解的剂量依赖性。
图2为化合物1对SOS1降解的时间依赖性。
图3为化合物1对MIA-paca-2的增殖抑制作用。
具体实施方式
如上所述的化合物或其药学上可接受的盐的制备方法,其中一种合成路线包括以下几个合成路线。
合成路线I:
合成路线II:
合成路线III:
合成路线IV:
以下结合具体实施例,对本发明进行进一步说明。
实施例1
(2S,4R)-1-((S)-2-(7-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)庚胺基)-3,3-二甲基丁酰)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺
本实施例化合物1的合成路线如合成路线I、合成路线II。具体合成步骤如下:
将S-1-1(2g,9.7mmol;1.0eq.)溶解于20mL四氢呋喃中。然后在室温下添加(R)-2-甲基丙烷-2-亚砜酰胺(1.8g,14.5mmol;1.5eq.)和Ti(OEt)4(5.5g,24.3mmol;2.5eq.)。在80℃搅拌过夜后,将反应混合物冷却至室温,并用冰水淬灭,用乙酸乙酯萃取,合并有机相,无水Na2SO4干燥,减压去除溶剂,得到粗产物。粗产物通过快速色谱柱纯化,得到淡黄色固体S-1-2,收率:79%。
将S-1-2(2.4g,7.77mmol;1.0eq.)溶于四氢呋喃(50mL)和水(1mL)的混合溶液中,在-78℃下缓慢加入NaBH4(531mg,14.0mmol;1.8eq.),然后在室温下搅拌3h。用冰水淬灭反应,用乙酸乙酯萃取,合并有机相,无水Na2SO4干燥。反应生成的非对映体混合物,经快速色谱分离,获得白色固体S-1-3,收率:85%。
向S-1-3(2.0g,6.6mmol)中加入4M HCl的1,4-二氧六环溶液9mL,在室温下搅拌1h。减压除去溶剂,得到中间体S-1-4。收率:96%。1H NMR(400MHz,DMSO-d6)δ8.72(s,3H),7.67(d,J=1.5Hz,1H),7.31(d,J=1.5Hz,1H),4.64(q,1H),1.54(d,J=6.8Hz,3H).
然后将LYS-1-4溶解在水中,调节pH至8-9,用乙酸乙酯萃取,合并有机相,无水Na2SO4干燥。在真空中浓缩以得到对应的游离氨基化合物。
向S-2-1(10g,47.4mmol;1.0eq.)的乙腈溶液(100mL)中加入甲烷磺酸(3.6g,379.2mmol;8.0eq.)。反应混合物在100℃下搅拌过夜。经UPLC-MS检测反应完毕后,将混合物冷却至室温。向反应混合物中滴加NaHCO3水溶液,调节pH至碱性,静置片刻后有沉淀产生,抽滤,冻干后得到粗产品S-2-2。收率:90%。UPLC-MS calculated for C11H12N2O3[M+H]+:220.23,found:220.91.UPLC-retention time:5.4min.1H NMR(400MHz,DMSO-d6)δ12.02(s,1H),7.35(s,1H),7.02(s,1H),3.84(s,3H),3.81(s,3H),2.27(s,3H).
向S-2-2(9.3g,42.6mmol;1.0eq.)的二氯甲烷(100mL)悬浮液中加入2,4,6-三异丙基苯磺酰氯(15.4g,51.1mmol;1.2eq.)、DMAP(524mg,4.3mmol;0.1eq.)和Et3N(12.9g,127.8mmol;3.0eq.)。反应混合物在室温下搅拌12h。用二氯甲烷稀释溶剂,加入NaHCO3水溶液,并用DCM萃取。合并的有机层用无水Na2SO4干燥,过滤,并在真空中去除溶剂。粗产物通过快速色谱柱纯化,得到所需产物S-2-3,收率:67%。UPLC-MS calculated for C26H34N2O5S[M+H]+:486.62,found:487.35.UPLC-retention time:8.0min.1H NMR(400MHz,Chloroform-d)δ7.30(s,1H),7.20(s,2H),7.07(s,1H),4.29(p,J=6.8Hz,2H),4.03(d,J=2.4Hz,6H),3.10–2.78(m,1H),2.59(s,3H),1.25(dd,J=6.8,1.5Hz,18H)。
将S-2-3(7.0g,14.4mmol;1.0eq.)和S-1-4(3.5g,14.4mmol;1.0eq.)溶解在50mL异丙醇中,95℃下搅拌过夜。在UPLC-MS证明起始材料完全转化后,将混合物冷却至室温。在真空中去除溶剂。粗产物通过快速色谱柱纯化,得到中间体S-2-4,收率:91%。1H NMR(400MHz,Chloroform-d)δ7.14(s,1H),7.07(d,J=1.3Hz,1H),6.95(d,J=1.3Hz,1H),6.88(s,1H),6.01–5.91(m,1H),5.69(s,1H),3.95–3.91(m,6H),2.61(s,3H),1.72(d,J=6.9Hz,3H)。
将S-2-4(2400mg,5.87mmol;1.0eq.)、(2-(羟甲基)苯基)硼酸(981mg,6.45mmol;1.1eq.)、Pd(PPh3)4(678mg,0.587mmol;0.1eq.)和Cs2CO3(5739mg,17.6mmol;3.0eq.)溶于四氢呋喃和水的混合溶液中,充氩气保护,在70℃条件下搅拌过夜。TLC检测反应完毕后,将反应液冷却至室温,并用乙酸乙酯和水萃取。混合有机层用盐水清洗,并用无水Na2SO4干燥,在减压下除去溶剂。粗产物通过快速色谱柱纯化,得到所需化合物S-2-5,收率:76%。
向S-2-5(500mg,1.1mmol;1.0eq.)的二氯甲烷(10mL)溶液中缓慢加入戴斯-马丁氧化剂(1462mg,3.45mmol;3.0eq.)。室温下搅拌5h,TLC检测反应完成。向反应混合物中加入Na2S2O4和NaHCO3的水溶液,并在室温下再搅拌30min。用乙酸乙酯萃取溶液,用盐水洗涤。合并的有机层用无水Na2SO4干燥,并在真空中浓缩。粗产物通过快速色谱柱进一步纯化,得到化合物S-2-6,收率:59%。1H NMR(400MHz,Chloroform-d)δ10.10(s,1H),7.95(d,J=7.7Hz,1H),7.59(t,J=7.5Hz,1H),7.44(t,J=8.3Hz,2H),7.18(s,1H),7.16–7.12(m,2H),6.96(s,1H),6.08–5.99(m,2H),3.98–3.93(m,6H),2.63(s,3H),1.81(d,J=6.3Hz,3H)。
将V-1-1(100mg,0.215mmol;1.0eq.)、7-((叔丁氧羰基)氨基)庚酸(52mg,0.215mmol;1.0eq.)、HATU(122mg,0.322mmol;1.5eq.)和DIPEA(111mg,0.858mmol;4.0eq.)溶于3mL N,N-二甲基甲酰胺,室温下搅拌6h,UPLC-MS检测反应完毕后,用水和乙酸乙酯稀释反应混合物。分离有机层,用盐水洗涤,并用无水Na2SO4干燥。溶液在真空下被除去。然后通过快速色谱柱纯化得到粗产品。将所得粗产品溶于二氯甲烷,加入4M HCl的1,4-二氧六环溶液2mL,在室温下搅拌1h。减压除去溶剂,得到中间体V-1-2。两步收率:75%。
将S-2-6(70mg,0.161mmol;1.0eq.)和V-1-2(90mg,0.161mmol;1.0eq.)溶于1,2-二氯乙烷(5mL),室温下搅拌1h后缓慢加入NaBH(OAc)3(68mg,0.323mmol;2.0eq.),继续室温搅拌过夜,UPLC-MS检测反应完毕后,用水稀释反应混合物,用二氯甲烷萃取,并用无水Na2SO4干燥,在真空中除去溶剂。粗产物通过prep-HPLC纯化,得到实施例1化合物,冷冻干燥后为白色粉末,收率:31%。1H NMR(400MHz,Chloroform-d)δ8.64(s,1H),7.44(t,J=6.0Hz,1H),7.38–7.34(m,1H),7.34–7.29(m,4H),7.28–7.25(m,3H),7.17(s,2H),7.13(s,1H),7.07(s,1H),6.40(d,J=9.0Hz,1H),6.32(d,J=8.2Hz,1H),6.08–5.99(m,1H),4.62(t,J=8.1Hz,1H),4.55–4.45(m,2H),4.39(s,1H),4.33–4.26(m,1H),3.95–3.90(m,4H),3.87(s,3H),3.71(s,2H),3.51(dd,J=11.2,3.5Hz,1H),2.59(s,4H),2.47(s,3H),2.44–2.39(m,2H),2.37–2.30(m,1H),2.16–2.02(m,3H),1.75(d,J=6.8Hz,3H),1.54–1.44(m,2H),1.33–1.25(m,3H),1.16–1.06(m,4H),0.91(s,9H).13C NMR(101MHz,Chloroform-d)δ173.86,171.74,171.14,162.85,157.59,154.38,150.47,148.48,148.35,148.29,147.28,140.88,136.72,131.72,130.93,130.13,129.83,129.54,128.12,127.70,127.45,125.86,121.81,107.05,106.56,100.33,69.84,68.05,58.84,57.46,56.94,56.34,56.21,51.67,49.05,45.52,43.21,36.38,36.25,35.29,29.78,29.27,28.77,26.64,26.49,26.36,25.68,25.33,21.96,16.11。
实施例2
(2S,4R)-1-((S)-2-(6-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)己胺基)-3,3-二甲基丁酰)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺
本实施例化合物2的合成路线如合成路线I、合成路线II。具体合成步骤如下:
将实施例1中7-((叔丁氧羰基)氨基)庚酸替换为6-((叔丁氧羰基)氨基)己酸,其余与实施例1相同。总收率:3.6%。1H NMR(400MHz,DMSO-d6)δ8.94(s,1H),8.55(t,J=6.0Hz,1H),8.12(d,J=8.3Hz,1H),7.84(d,J=9.3Hz,1H),7.62(s,1H),7.44–7.32(m,7H),7.28–7.22(m,4H),7.03(s,1H),5.99–5.88(m,1H),5.12(s,1H),4.50(d,J=9.4Hz,1H),4.44–4.35(m,2H),4.31(s,1H),4.17(dd,J=15.9,5.4Hz,1H),3.83(s,6H),3.65–3.57(m,4H),2.41–2.38(m,7H),2.24–2.15(m,1H),2.08–1.95(m,2H),1.91–1.82(m,1H),1.68(d,J=6.9Hz,3H),1.48–1.35(m,3H),1.31(s,3H),1.30–1.26(m,1H),0.89(s,9H)。
实施例3
(2S,4R)-1-((S)-2-(8-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)辛胺基)-3,3-二甲基丁酰)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺
本实施例化合物3的合成路线如合成路线I、合成路线II。具体合成步骤如下:
将实施例1中7-((叔丁氧羰基)氨基)庚酸替换为8-((叔丁氧羰基)氨基)辛酸,其余与实施例1相同。总收率:3.9%。1H NMR(400MHz,Chloroform-d)δ8.65(s,1H),7.41(t,J=6.0Hz,1H),7.35–7.26(m,8H),7.20–7.16(m,2H),7.14(s,1H),7.03(s,1H),6.30(d,J=9.0Hz,1H),6.16(d,J=8.3Hz,1H),6.07–5.99(m,1H),4.63(t,J=8.2Hz,1H),4.56–4.47(m,2H),4.36(s,1H),4.32–4.24(m,1H),3.98(d,J=11.4Hz,1H),3.95(s,3H),3.92(s,3H),3.73(d,J=5.6Hz,2H),3.48(dd,J=11.4,3.3Hz,1H),2.60(s,3H),2.48(s,3H),2.45–2.37(m,3H),2.37–2.32(m,1H),2.20–2.06(m,5H),1.76(d,J=6.8Hz,3H),1.59–1.44(m,2H),1.32–1.25(m,3H),1.14–1.11(m,4H),0.90(s,9H)。
实施例4
(2S,4R)-1-((S)-2-(9-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)壬胺基)-3,3-二甲基丁酰)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺
本实施例化合物4的合成路线如合成路线I、合成路线II。具体合成步骤如下:
将实施例1中7-((叔丁氧羰基)氨基)庚酸替换为9-((叔丁氧羰基)氨基)壬酸,其余与实施例1相同。总收率:2.9%。1H NMR(400MHz,Chloroform-d)δ8.65(s,1H),7.42–7.37(m,1H),7.35–7.27(m,8H),7.22–7.17(m,2H),7.15(s,1H),7.06(s,1H),6.27(d,J=8.9Hz,1H),6.20(s,1H),6.04(p,J=6.9Hz,1H),4.66(t,J=8.1Hz,1H),4.56–4.48(m,2H),4.41(s,1H),4.30(dd,J=15.0,5.3Hz,1H),3.99(d,J=11.4Hz,1H),3.95(s,3H),3.93(s,3H),3.80(q,J=12.9Hz,2H),3.49(dd,J=11.3,3.4Hz,1H),2.61(s,3H),2.49–2.37(m,7H),2.15(dt,J=12.0,7.4Hz,7H),1.78(d,J=6.8Hz,3H),1.53(dt,J=15.9,7.8Hz,2H),1.32(d,J=5.8Hz,3H),1.12(s,4H),0.91(s,9H)。
实施例5
(2S,4R)-1-((S)-2-(10-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)癸胺基)-3,3-二甲基丁酰)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺
本实施例化合物5的合成路线如合成路线I、合成路线II。具体合成步骤如下:
将实施例1中7-((叔丁氧羰基)氨基)庚酸替换为9-((叔丁氧羰基)氨基)壬酸,其余与实施例1相同。总收率:2.7%。1H NMR(400MHz,Chloroform-d)δ8.66(s,1H),7.41–7.37(m,1H),7.35–7.28(m,8H),7.21(s,2H),7.17(s,1H),7.04(s,1H),6.26(d,J=8.8Hz,1H),6.16(s,1H),6.09–6.00(m,1H),4.68(t,J=8.1Hz,1H),4.58–4.47(m,2H),4.44(s,1H),4.34–4.27(m,1H),4.04(d,J=11.4Hz,1H),3.96(s,3H),3.94(s,3H),3.88–3.77(m,2H),3.52(dd,J=11.3,3.4Hz,1H),2.62(s,3H),2.54–2.42(m,7H),2.23–1.98(m,9H),1.78(d,J=6.7Hz,3H),1.58–1.50(m,2H),1.40–1.31(m,3H),1.14–1.11(m,4H),0.91(s,9H)。
实施例6
(2S,4R)-N-((S)-3-((6-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)己基)氨基)-1-(4-(4-甲基噻唑-5-基)苯基)-3-氧丙基)-4-羟基-1-((R)-3-甲基-2-(3-甲基异恶唑-5-基)丁酰)吡咯烷-2-甲酰胺
本实施例化合物6的合成路线如合成路线I、合成路线III。具体合成步骤如下:
将V-2-1(100mg,0.185mmol;1.0eq.)、叔丁基(6-氨基己基)氨基甲酸酯(40mg,0.185mmol;1.0eq.)、HATU(105mg,0.277mmol;1.5eq.)和DIPEA(95mg,0.740mmol;4.0eq.)溶于3mL N,N-二甲基甲酰胺,室温下搅拌6h,UPLC-MS检测反应完毕后,用水和乙酸乙酯稀释反应混合物。分离有机层,用盐水洗涤,并用无水Na2SO4干燥。溶液在真空下被除去。然后通过快速色谱柱纯化得到粗产品。将所得粗产品溶于二氯甲烷,加入4M HCl的1,4-二氧六环溶液2mL,在室温下搅拌1h。减压除去溶剂,得到中间体V-2-2。两步收率:72%
将S-2-6(34mg,0.078mmol;1.0eq.)和V-2-2(50mg,0.078mmol;1.0eq.)溶于1,2-二氯乙烷(5mL),室温下搅拌1h后缓慢加入NaBH(OAc)3(33mg,0.156mmol;2eq.),继续室温搅拌过夜,UPLC-MS检测反应完毕后,用水稀释反应混合物,用二氯甲烷萃取,并用无水Na2SO4干燥,在真空中除去溶剂。粗产物通过prep-HPLC纯化,得到实施例6,冷冻干燥后为白色粉末,收率:28%。1H NMR(400MHz,DMSO-d6)δ8.91(s,1H),8.24(s,1H),8.14(d,J=8.2Hz,1H),7.62(s,1H),7.46(s,1H),7.41–7.23(m,10H),7.01(s,1H),5.97–5.87(m,1H),5.28–5.06(m,1H),4.40–4.19(m,2H),3.82(s,6H),3.37–3.25(m,4H),3.04–2.77(m,3H),2.65–2.50(m,3H),2.39(d,J=3.3Hz,6H),2.31–2.17(m,2H),2.14(d,J=9.8Hz,3H),2.03–1.89(m,1H),1.84–1.70(m,1H),1.67(d,J=6.9Hz,3H),1.28–1.13(m,6H),1.11–0.95(m,5H),0.91(dd,J=6.6,1.7Hz,3H),0.73(dd,J=12.7,6.7Hz,3H)。
实施例7
(2S,4R)-N-((S)-3-((7-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)庚基)氨基)-1-(4-(4-甲基噻唑-5-基)苯基)-3-氧丙基)-4-羟基-1-((R)-3-甲基-2-(3-甲基异恶唑-5-基)丁酰)吡咯烷-2-甲酰胺
本实施例化合物7的合成路线如合成路线I、合成路线III。具体合成步骤如下:
将实施例6中的叔丁基(6-氨基己基)氨基甲酸酯替换为叔丁基(7-氨基庚基)氨基甲酸酯,其余与实施例6相同。总收率:3.1%。1H NMR(400MHz,DMSO-d6)δ10.35(d,J=7.9Hz,1H),9.37(s,1H),8.96(s,1H),8.21(s,1H),7.83–7.75(m,1H),7.48(s,1H),7.41–7.25(m,10H),6.11–6.00(m,1H),5.24–5.05(m,1H),4.39–4.17(m,2H),4.10–4.04(m,2H),3.90(d,J=7.4Hz,6H),3.57–3.25(m,4H),3.03–2.79(m,2H),2.73–2.59(m,7H),2.39(s,3H),2.34–2.18(m,1H),2.14(d,J=10.7Hz,3H),2.06–1.90(m,1H),1.79(d,J=6.9Hz,3H),1.75–1.63(m,1H),1.43(s,2H),1.27–1.12(m,4H),1.05–0.96(m,6H),0.91(dd,J=6.6,2.2Hz,3H),0.73(dd,J=12.5,6.6Hz,3H)。
实施例8
(2S,4R)-N-((S)-3-((8-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)辛基)氨基)-1-(4-(4-甲基噻唑-5-基)苯基)-3-氧丙基)-4-羟基-1-((R)-3-甲基-2-(3-甲基异恶唑-5-基)丁酰)吡咯烷-2-甲酰胺
本实施例化合物8的合成路线如合成路线I、合成路线III。具体合成步骤如下:
将实施例6中的叔丁基(6-氨基己基)氨基甲酸酯替换为叔丁基(8-氨基辛基)氨基甲酸酯,其余与实施例6相同。总收率:3.3%。1H NMR(400MHz,DMSO-d6)δ8.91(s,1H),8.23(s,1H),8.14(d,J=8.3Hz,1H),7.62(s,1H),7.49(s,1H),7.43–7.22(m,10H),7.01(s,1H),5.99–5.87(m,1H),5.23–5.05(m,1H),4.44–4.18(m,3H),3.82(s,6H),3.72(s,3H),3.56–3.22(m,4H),3.03–2.78(m,2H),2.39(d,J=4.9Hz,6H),2.14(d,J=9.5Hz,4H),2.02–1.77(m,2H),1.68(d,J=7.0Hz,3H),1.33–1.15(m,6H),1.11–0.96(m,11H),0.92(d,J=6.5Hz,3H),0.74(dd,J=12.8,6.6Hz,3H)。
实施例9
(2S,4R)-N-((S)-3-((9-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)壬基)氨基)-1-(4-(4-甲基噻唑-5-基)苯基)-3-氧丙基)-4-羟基-1-((R)-3-甲基-2-(3-甲基异恶唑-5-基)丁酰)吡咯烷-2-甲酰胺
本实施例化合物9的合成路线如合成路线I、合成路线III。具体合成步骤如下:
将实施例6中的叔丁基(6-氨基己基)氨基甲酸酯替换为叔丁基(9-氨基壬基)氨基甲酸酯,其余与实施例6相同。总收率:2.8%。1H NMR(400MHz,DMSO-d6)δ8.92(s,1H),8.22(s,1H),8.15(d,J=8.2Hz,1H),7.62(s,1H),7.51(d,J=5.7Hz,1H),7.43–7.22(m,10H),7.01(s,1H),5.97–5.88(m,1H),5.25–5.06(m,1H),4.45–4.20(m,3H),3.82(s,6H),3.73–3.62(m,2H),3.57–3.22(m,3H),3.01–2.77(m,2H),2.66–2.50(m,3H),2.39(d,J=4.6Hz,6H),2.36–2.18(m,2H),2.14(d,J=9.2Hz,3H),2.01–1.89(m,1H),1.68(d,J=6.8Hz,3H),1.34–1.13(m,6H),1.09–0.96(m,11H),0.92(d,J=6.3Hz,3H),0.74(dd,J=12.8,6.6Hz,3H)。
实施例10
(2S,4R)-N-((S)-3-((10-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)癸基)氨基)-1-(4-(4-甲基噻唑-5-基)苯基)-3-氧丙基)-4-羟基-1-((R)-3-甲基-2-(3-甲基异恶唑-5-基)丁酰)吡咯烷-2-甲酰胺
本实施例化合物10的合成路线如合成路线I、合成路线III。具体合成步骤如下:
将实施例6中的叔丁基(6-氨基己基)氨基甲酸酯替换为叔丁基(10-氨基癸基)氨基甲酸酯,其余与实施例6相同。总收率:3.0%。1H NMR(400MHz,DMSO-d6)δ9.14(s,1H),8.95(s,1H),7.80–7.69(m,2H),7.45–7.21(m,11H),7.06(s,1H),6.02–5.91(m,1H),5.13–5.06(m,1H),4.34–4.20(m,1H),4.09(s,2H),3.85(s,6H),3.74–3.66(m,1H),3.57–3.38(m,3H),3.01–2.78(m,2H),2.73–2.62(m,3H),2.41(d,J=4.8Hz,6H),2.26–2.18(m,1H),2.15(d,J=9.6Hz,3H),2.01–1.91(m,1H),1.71(d,J=6.9Hz,3H),1.42(s,2H),1.23–1.13(m,6H),1.09–0.98(m,14H),0.92(d,J=6.5Hz,3H),0.77–0.71(m,3H)。
实施例11
(2S,4R)-N-((S)-3-((11-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)十一烷基)氨基)-1-(4-(4-甲基噻唑-5-基)苯基)-3-氧丙基)-4-羟基-1-((R)-3-甲基-2-(3-甲基异恶唑-5-基)丁酰)吡咯烷-2-甲酰胺
本实施例化合物11的合成路线如合成路线I、合成路线III。具体合成步骤如下:
将实施例6中的叔丁基(6-氨基己基)氨基甲酸酯替换为叔丁基(11-氨基十一烷基)氨基甲酸酯,其余与实施例6相同。总收率:2.5%。1H NMR(400MHz,DMSO-d6)δ8.93(s,1H),8.27(s,1H),8.17(d,J=8.2Hz,1H),7.63(s,1H),7.52(s,1H),7.43–7.22(m,10H),7.01(s,1H),5.98–5.89(m,1H),5.24–5.07(m,1H),4.39–4.25(m,4H),3.82(s,6H),3.80–3.76(m,2H),3.73–3.67(m,1H),3.57–3.26(m,2H),3.00–2.79(m,2H),2.65–2.52(m,3H),2.39(d,J=4.6Hz,6H),2.31–2.19(m,1H),2.14(d,J=8.9Hz,3H),2.02–1.79(m,1H),1.68(d,J=6.9Hz,3H),1.32(s,2H),1.24–1.14(m,4H),1.11–0.99(m,15H),0.92(dd,J=6.6,2.1Hz,3H),0.73(dd,J=12.4,6.7Hz,3H)。
实施例12
(2S,4R)-N-((S)-3-((12-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)十二烷基)氨基)-1-(4-(4-甲基噻唑-5-基)苯基)-3-氧丙基)-4-羟基-1-((R)-3-甲基-2-(3-甲基异恶唑-5-基)丁酰)吡咯烷-2-甲酰胺
本实施例化合物12的合成路线如合成路线I、合成路线III。具体合成步骤如下:
将实施例6中的叔丁基(6-氨基己基)氨基甲酸酯替换为叔丁基(12-氨基十二烷基)氨基甲酸酯,其余与实施例6相同。总收率:2.6%。1H NMR(400MHz,DMSO-d6)δ8.93(s,1H),8.23(s,1H),8.15(d,J=8.2Hz,1H),7.62(s,1H),7.49(s,1H),7.42–7.23(m,10H),7.01(s,1H),5.99–5.87(m,1H),5.26–5.05(m,1H),4.38–4.20(m,3H),3.82(s,6H),3.76(s,2H),3.70(d,J=6.4Hz,1H),3.52–3.33(m,3H),3.01–2.77(m,2H),2.66–2.50(m,3H),2.39(d,J=5.1Hz,6H),2.28–2.18(m,1H),2.14(d,J=9.0Hz,3H),2.02–1.90(m,1H),1.67(d,J=6.9Hz,3H),1.37–1.26(m,2H),1.20–1.01(m,21H),0.94–0.89(m,3H),0.73(dd,J=12.5,6.7Hz,3H)。
实施例13
5-((6-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)己基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮
本实施例化合物13的合成路线如合成路线I、合成路线IV。具体合成步骤如下:
将C-1-1(200mg,0.725mmol;1.0eq.)、叔丁基(6-氨基己基)氨基甲酸酯(156mg,0.725mmol;1.0eq.)和DIPEA(374mg,2.90mmol;4.0eq.)溶于3mL N,N-二甲基甲酰胺,90℃下搅拌过夜,UPLC-MS检测反应完毕后,用水和乙酸乙酯稀释反应混合物。分离有机层,用盐水洗涤,并用无水Na2SO4干燥。溶液在真空下被除去。然后通过快速色谱柱纯化得到粗产品。将所得粗产品溶于二氯甲烷,加入4M HCl的1,4-二氧六环溶液3mL,在室温下搅拌1h。减压除去溶剂,得到中间体C-1-2。两步收率:53%。
将S-2-6(50mg,0.115mmol;1.0eq.)和C-1-2(47mg,0.115mmol;1.0eq.)溶于1,2-二氯乙烷(5mL),室温下搅拌1h后缓慢加入NaBH(OAc)3(73mg,0.345mmol;3.0eq.),继续室温搅拌过夜,UPLC-MS检测反应完毕后,用水稀释反应混合物,用二氯甲烷萃取,并用无水Na2SO4干燥,在真空中除去溶剂。粗产物通过prep-HPLC纯化,得到化合物13,冷冻干燥后为黄色粉末,收率:21%。1H NMR(400MHz,DMSO-d6)δ11.04(s,1H),8.23–8.11(m,2H),7.63(s,1H),7.51(d,J=7.5Hz,2H),7.42(s,1H),7.29(s,2H),7.24(s,1H),7.09(s,1H),7.01(s,1H),6.89(s,1H),6.78(d,J=8.5Hz,1H),5.97–5.87(m,1H),4.99(dd,J=13.2,5.3Hz,1H),3.83(s,6H),3.75(s,2H),3.10–3.04(m,2H),2.87–2.78(m,1H),2.39(s,3H),1.95(s,1H),1.68(d,J=6.9Hz,3H),1.47(s,2H),1.41–1.31(m,3H),1.23–1.15(m,8H)。
实施例14
5-((7-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)庚基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮
本实施例化合物14的合成路线如合成路线I、合成路线IV。具体合成步骤如下:
将实施例13中的叔丁基(6-氨基己基)氨基甲酸酯替换为叔丁基(7-氨基庚基)氨基甲酸酯,其余与实施例13相同。总收率:1.8%。1H NMR(400MHz,DMSO-d6)δ11.05(s,1H),8.20–8.14(m,2H),7.63(s,1H),7.55–7.48(m,2H),7.41(s,1H),7.30–7.29(m,2H),7.24(s,1H),7.10(t,J=5.4Hz,1H),7.00(s,1H),6.89(s,1H),6.78(d,J=8.6Hz,1H),5.97–5.87(m,1H),4.99(dd,J=12.9,5.4Hz,1H),3.82(d,J=2.2Hz,6H),3.79(s,2H),3.09–3.06(m,2H),2.86–2.79(m,1H),2.39(s,3H),1.94–1.91(m,1H),1.68(d,J=6.9Hz,3H),1.51–1.46(m,2H),1.37–1.34(m,3H),1.32–1.30(m,2H),1.20–1.18(m,8H)。
实施例15
5-((8-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)辛基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮
本实施例化合物15的合成路线如合成路线I、合成路线IV。具体合成步骤如下:
将实施例13中的叔丁基(6-氨基己基)氨基甲酸酯替换为叔丁基(8-氨基辛基)氨基甲酸酯,其余与实施例13相同。总收率:2.1%。1H NMR(400MHz,DMSO-d6)δ11.05(s,1H),8.19(s,1H),8.14(d,J=8.2Hz,1H),7.62(s,1H),7.54–7.46(m,2H),7.42(s,1H),7.28(s,2H),7.24(s,1H),7.08(t,J=5.2Hz,1H),7.00(s,1H),6.88(s,1H),6.78(dd,J=8.4,2.1Hz,1H),5.97–5.88(m,1H),4.99(dd,J=12.9,5.4Hz,1H),3.82(s,6H),3.73(s,2H),3.08(d,J=6.2Hz,2H),2.89–2.78(m,1H),2.39(s,3H),1.99–1.91(m,1H),1.68(d,J=6.9Hz,3H),1.55–1.45(m,2H),1.37–1.24(m,5H),1.22–1.10(m,10H)。
实施例16
5-((9-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)壬基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮
本实施例化合物16的合成路线如合成路线I、合成路线IV。具体合成步骤如下:
将实施例13中的叔丁基(6-氨基己基)氨基甲酸酯替换为叔丁基(9-氨基壬基)氨基甲酸酯,其余与实施例13相同。总收率:1.9%。1H NMR(400MHz,DMSO-d6)δ11.05(s,1H),8.20(s,1H),8.14(d,J=8.3Hz,1H),7.62(s,1H),7.51(d,J=7.8Hz,2H),7.41(s,1H),7.30(s,2H),7.23(s,1H),7.08(t,J=5.3Hz,1H),7.01(s,1H),6.89(s,1H),6.78(d,J=8.6Hz,1H),5.98–5.88(m,1H),4.99(dd,J=13.0,5.4Hz,1H),3.82(s,6H),3.80(s,2H),3.08(q,J=6.4Hz,2H),2.89–2.77(m,1H),2.39(s,3H),1.99–1.91(m,1H),1.68(d,J=6.9Hz,3H),1.55–1.45(m,2H),1.37–1.25(m,5H),1.22–1.09(m,12H)。
实施例17
5-((10-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)癸基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮
本实施例化合物17的合成路线如合成路线I、合成路线IV。具体合成步骤如下:
将实施例13中的叔丁基(6-氨基己基)氨基甲酸酯替换为叔丁基(10-氨基癸基)氨基甲酸酯,其余与实施例13相同。总收率:1.9%。1H NMR(400MHz,DMSO-d6)δ11.05(s,1H),9.33(s,1H),8.09(s,1H),7.79–7.75(m,1H),7.51–7.49(m,1H),7.46(s,1H),7.42–7.39(m,2H),7.33–7.29(m,2H),7.22(s,1H),7.17(t,J=5.3Hz,1H),6.89(s,1H),6.79(dd,J=8.5,2.0Hz,1H),6.07–5.98(m,1H),4.99(dd,J=12.9,5.3Hz,1H),4.08(s,2H),3.88(d,J=6.5Hz,6H),3.11–3.06(m,2H),2.88–2.78(m,1H),2.57(s,3H),1.98–1.96(m,1H),1.77(d,J=7.0Hz,3H),1.55–1.51(m,2H),1.46–1.40(m,5H),1.11–1.06(m,14H)。
实施例18
5-((11-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)十一烷基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮
本实施例化合物18的合成路线如合成路线I、合成路线IV。具体合成步骤如下:
将实施例13中的叔丁基(6-氨基己基)氨基甲酸酯替换为叔丁基(11-氨基十一烷基)氨基甲酸酯,其余与实施例13相同。总收率:1.5%。1H NMR(400MHz,DMSO-d6)δ11.04(s,1H),10.35(d,J=8.0Hz,1H),9.37(s,2H),8.22(s,1H),7.82–7.75(m,1H),7.50(d,J=8.4Hz,1H),7.48(d,J=1.4Hz,1H),7.42–7.39(m,2H),7.35–7.33(m,1H),7.30(s,1H),6.89(d,J=2.1Hz,1H),6.80(dd,J=8.5,2.1Hz,1H),6.06(p,J=7.0Hz,1H),4.99(dd,J=12.9,5.3Hz,1H),4.08(t,J=5.9Hz,2H),3.90(d,J=8.2Hz,6H),3.09(t,J=7.0Hz,2H),2.90–2.78(m,1H),2.63(s,3H),1.98–1.92(m,1H),1.80(d,J=6.9Hz,3H),1.53–1.48(m,2H),1.34–1.27(m,2H),1.26–1.05(m,19H)。
实施例19
5-((12-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)十二烷基)氨基)-2-(2,6-二氧哌啶-3-基)异吲哚啉-1,3-二酮
本实施例化合物19的合成路线如合成路线I、合成路线IV。具体合成步骤如下:
将实施例13中的叔丁基(6-氨基己基)氨基甲酸酯替换为叔丁基(11-氨基十一烷基)氨基甲酸酯,其余与实施例13相同。总收率:1.2%。1H NMR(400MHz,DMSO-d6)δ11.05(s,1H),8.27(s,1H),8.15(d,J=8.2Hz,1H),7.62(s,1H),7.54–7.45(m,2H),7.42(s,1H),7.28(s,2H),7.25(s,1H),7.09(t,J=5.3Hz,1H),7.00(s,1H),6.89(s,1H),6.78(dd,J=8.4,2.0Hz,1H),5.99–5.88(m,1H),4.99(dd,J=12.9,5.4Hz,1H),3.82(s,6H),3.72(s,2H),3.07(q,J=6.4Hz,2H),2.89–2.78(m,1H),2.39(s,3H),1.98–1.91(m,1H),1.68(d,J=6.9Hz,3H),1.54–1.45(m,2H),1.36–1.25(m,5H),1.21–1.08(m,18H)。
实施例20
(2S,4R)-1-((S)-2-(3-(4-(((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-))基)氨基)乙基)噻吩-3-基)苄基)氨基)甲基)哌啶-1-基)-3-氧代丙酰胺基)-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑)-5-基)苄基)吡咯烷-2-甲酰胺
本实施例化合物20的合成路线如合成路线I、合成路线II。具体合成步骤如下:
将实施例1中的7-((叔丁氧羰基)氨基)庚酸替换为3-(4-(((叔丁氧羰基)氨基)甲基)哌啶-1-基)-3-氧代丙酸,其余与实施例1相同。总收率:1.5%。1H NMR(400MHz,DMSO-d6)δ8.94(s,1H),8.56(t,J=6.1Hz,1H),8.25–8.17(m,2H),8.16–8.11(m,1H),7.62(s,1H),7.46(s,1H),7.42–7.31(m,5H),7.29–7.20(m,4H),7.04(d,J=10.0Hz,1H),6.00–5.87(m,1H),4.50(dd,J=9.4,4.2Hz,1H),4.40(dd,J=14.8,6.7Hz,2H),4.31(s,1H),4.28–4.13(m,3H),3.83(d,J=2.9Hz,6H),3.62–3.54(m,6H),3.45–3.23(m,4H),2.89–2.74(m,1H),2.40(d,J=3.3Hz,6H),2.30(s,2H),2.05–1.81(m,2H),1.68(d,J=6.9Hz,3H),1.62–1.46(m,3H),0.91(s,9H)。
实施例21
(2S,4R)-1-((S)-2-(3-(4-((4-(((2-(5-((R)-1-((6,7-二甲氧基-2-))甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)甲基)哌啶-1-基)甲基)哌啶-1-基)-3-氧代丙酰胺基)-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺
本实施例化合物21的合成路线如合成路线I、合成路线II。具体合成步骤如下:
将实施例1中的7-((叔丁氧羰基)氨基)庚酸替换为3-(4-(4-(((叔丁氧基羰基)氨基)甲基)哌啶-1-基)甲基)吡啶-1-基)-3-氧代丙酸,其余与实施例1相同。总收率:0.9%。1H NMR(400MHz,DMSO-d6)δ8.95(s,1H),8.61–8.52(m,1H),8.22–8.14(m,2H),8.11(d,J=8.2Hz,1H),7.61(s,1H),7.46–7.42(m,2H),7.40–7.32(m,4H),7.29–7.22(m,4H),7.01(s,1H),5.97–5.87(m,1H),4.50(d,J=9.4Hz,1H),4.45–4.35(m,2H),4.33–4.24(m,2H),4.18(dd,J=15.9,5.4Hz,1H),3.83(s,6H),3.78–3.69(m,2H),3.67–3.48(m,10H),2.93–2.84(m,1H),2.71–2.61(m,2H),2.40(d,J=4.0Hz,6H),2.27(d,J=6.6Hz,2H),2.04–1.81(m,6H),1.68(d,J=7.0Hz,3H),1.64–1.37(m,7H),0.90(s,9H)。
实施例22
1-(3-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-4-基)氨基)乙基)噻吩-3-基)苄基)氨基)丙基)-N-((S)-1-((2S,4R)-4-羟基-2-((4-(4-甲基噻唑-5-基)苄基)氨基甲酰基)吡咯烷-1-基)-3,3-二甲基-1-氧代丁-2-基)哌啶-4-甲酰胺
本实施例化合物22的合成路线如合成路线I、合成路线II。具体合成步骤如下:
将中间体V-1-2合成路线中的7-((叔丁氧基羰基)氨基)庚酸替换为1-(叔丁氧基羰基)哌啶-4-羧酸,其余与V-1-2相同。收率:62%。
将V-1-4(100mg,0.173mmol;1.0eq.)溶于10mL乙腈,加入K2CO3(60mg,0.432mmol;2.5eq.)和(3-溴丙基)氨基甲酸叔丁酯(49mg,0.208mmol;1.2eq.),在70℃条件下搅拌过夜,经UPLC-MS检测反应完毕后,在减压条件下蒸干溶剂,加入乙酸乙酯和水稀释,分离有机层,用盐水洗涤,并用无水Na2SO4干燥,利用快速色谱柱纯化,向所得产物中加入3mL盐酸1,4-二氧六环溶液(4M),室温搅拌一小时后蒸干溶剂,得到v-1-5,收率:72%。
将实施例1中的V-1-2替换为V-1-5,其余与实施例1相同。收率:31%。1H NMR(400MHz,DMSO-d6)δ8.95(s,1H),8.57(t,J=5.9Hz,1H),8.21(s,2H),8.15(d,J=8.1Hz,1H),7.79(d,J=8.9Hz,1H),7.62(s,1H),7.49(d,J=6.7Hz,1H),7.41–7.29(m,7H),7.02(s,1H),5.99–5.88(m,1H),4.49(d,J=9.3Hz,1H),4.44–4.35(m,3H),4.31(s,1H),4.17(dd,J=16.0,5.4Hz,2H),3.83(s,6H),3.76(s,2H),3.66–3.56(m,2H),2.83(d,J=10.6Hz,2H),2.66–2.50(m,3H),2.40(d,J=2.7Hz,6H),2.33–2.24(m,3H),2.03–1.94(m,1H),1.90–1.77(m,3H),1.68(d,J=6.9Hz,3H),1.58–1.41(m,5H),0.89(s,9H)。
实施例23
(2S,4R)-N-((S)-3-(4-(2-((2-(5-((R)-1-((6,7-dimethoxy-2-methylquinazolin-4-yl)))氨基)乙基)噻吩-3-基)苄基)氨基)乙基)哌啶-1-基)-1-(4-(4-甲基噻唑-5-基)苯基)-3-氧代丙基)-4-羟基-1-((R)-3-甲基-2-(3-甲基异恶唑-5-基)丁酰基)吡咯烷-2-甲酰胺
本实施例化合物23的合成路线如合成路线I、合成路线III。具体合成步骤如下:
将实施例6中的叔丁基(6-氨基己基)氨基甲酸酯替换为(2-(哌啶-4-基)乙基)氨基甲酸叔丁酯,其余与实施例6相同。总收率:2.1%。1H NMR(400MHz,DMSO-d6)δ8.92(d,J=8.9Hz,1H),8.28(s,1H),8.14(d,J=7.9Hz,1H),7.85(d,J=7.5Hz,1H),7.81(d,J=7.4Hz,1H),7.62(s,1H),7.40–7.25(m,10H),7.06–6.99(m,1H),5.93(q,J=7.0Hz,1H),5.16(t,J=7.8Hz,1H),4.34(d,J=7.8Hz,1H),4.29(t,J=7.8Hz,1H),4.23(s,2H),3.85(s,1H),3.83(d,J=3.2Hz,6H),3.71–3.61(m,4H),3.39–3.32(m,1H),2.93(t,J=5.4Hz,2H),2.85–2.61(m,3H),2.40(dd,J=6.6,2.0Hz,6H),2.32(s,1H),2.21(q,J=7.1Hz,1H),2.13(dt,J=11.5,3.8Hz,3H),1.96(d,J=7.6Hz,1H),1.67(d,J=6.9Hz,3H),1.59(s,2H),1.50(s,1H),1.40(d,J=14.5Hz,2H),1.12(s,1H),0.91(dd,J=6.5,3.5Hz,3H),0.81–0.60(m,5H)。
实施例24
(2S,4R)-1-((S)-2-(3-(4-(2-((2-(5-((R)-1-((6,7-二甲氧基-2-甲基喹唑啉-))4-基)氨基)乙基)噻吩-3-基)苄基)氨基)乙基)哌啶-1-基)-3-氧代丙酰胺基)-3,3-二甲基丁酰基)-4-羟基-N-(4-(4)-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺
本实施例化合物24的合成路线如合成路线I、合成路线II。具体合成步骤如下:
将实施例1中的7-((叔丁氧羰基)氨基)庚酸替换为3-(4-(2-((叔丁氧羰基)氨基)乙基)哌啶-1-基)-3-氧代丙酸,其余与实施例1相同。总收率:2.3%。1H NMR(400MHz,DMSO-d6)δ8.95(s,1H),8.64–8.55(m,1H),8.25(s,1H),8.17(dd,J=16.9,8.7Hz,2H),7.63(s,1H),7.49(s,1H),7.41–7.32(m,5H),7.31–7.24(m,4H),7.03(s,1H),5.99–5.87(m,1H),4.50(d,J=9.4Hz,1H),4.41–4.36(m,2H),4.33–4.23(m,4H),3.83(s,6H),3.76–3.57(m,6H),3.48–3.21(m,3H),2.94(s,1H),2.86–2.76(m,1H),2.40(s,6H),2.04–1.81(m,2H),1.68(d,J=6.8Hz,3H),1.32–1.17(m,3H),0.90(s,9H)。
实施例25
(2S,4R)-N-((S)-3-(4-((4-(((2-(5-((R)-1-((6,7-dimethoxy-2-methylquinazolin-4))-基)氨基)乙基)噻吩-3-基)苄基)氨基)甲基)哌啶-1-基)甲基)哌啶-1-基)-1-(4-(4-甲基噻唑-5-基)苯基)-3-氧代丙基)-4-羟基-1-((R)-3-甲基-2-(3-甲基异恶唑-5-基)丁酰基)吡咯烷-2-甲酰胺
本实施例化合物25的合成路线如合成路线I、合成路线III。具体合成步骤如下:
将实施例6中的叔丁基(6-氨基己基)氨基甲酸酯替换为((1-(哌啶-4-基甲基)哌啶-4-基)甲基)氨基甲酸叔丁酯,其余与实施例6相同。总收率:1.2%。1H NMR(400MHz,DMSO-d6)δ8.94(d,J=3.2Hz,1H),8.22(s,2H),8.11(d,J=8.1Hz,1H),7.61(s,1H),7.43–7.33(m,6H),7.27–7.22(m,5H),7.01(s,1H),5.96–5.87(m,1H),5.14(s,1H),4.31–4.21(m,3H),3.83(s,6H),3.32–3.22(m,8H),2.67–2.60(m,4H),2.41(s,3H),2.39(s,3H),2.31–2.28(m,1H),2.27–2.23(m,2H),2.17–2.15(m,2H),2.13(d,J=3.3Hz,1H),2.01–1.88(m,2H),1.68(d,J=6.8Hz,3H),1.61–1.50(m,8H),1.45–1.41(m,2H),1.39–1.33(m,2H),0.92(d,J=6.5Hz,3H),0.81–0.68(m,5H)。
实施例26
(2S,4R)-1-((S)-2-(4-(4-(2-(5-((R)-1-((6,7-dimethoxy-2-methylquinazolin-4-yl))氨基)乙基)噻吩-3-基)苄基)哌嗪-1-基)苯甲酰氨基)-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺
本实施例化合物26的合成路线如合成路线I、合成路线II。具体合成步骤如下:
将实施例1中的7-((叔丁氧羰基)氨基)庚酸替换为4-(4-(叔丁氧基羰基)哌嗪-1-基)苯甲酸,其余与实施例1相同。总收率:3.4%。1H NMR(400MHz,DMSO-d6)δ8.94(s,1H),8.57(t,J=6.0Hz,1H),8.21(s,1H),8.13(d,J=8.3Hz,1H),7.71(d,2H),7.62(s,1H),7.55(d,J=9.1Hz,1H),7.45(s,1H),7.39–7.35(m,6H),7.31–7.26(m,2H),7.02(s,1H),6.79(d,J=8.5Hz,2H),6.00–5.91(m,1H),4.72(d,J=9.1Hz,1H),4.45–4.32(m,3H),4.25–4.16(m,1H),3.82(d,J=3.7Hz,6H),3.69(s,3H),3.38(s,4H),3.05(t,J=5.0Hz,4H),2.43(s,2H),2.41(s,3H),2.39(s,3H),2.06–1.97(m,1H),1.93–1.84(m,1H),1.68(d,J=6.9Hz,3H),0.98(s,9H)。
实施例27、实施例化合物对PANC-1细胞中SOS1蛋白降解能力的评价
将人胰腺癌细胞PANC-1在含有10%PBS和2.5%马血清的DMEM高糖培养基(以下记作评价培养基)中以达到3×105/孔的量接种于6孔微孔培养板(Corning),培养过夜。在该培养物中添加含有实施例化合物的评价培养基中,使得实施例化合物的终浓度达到0.1、1和10μmol/L,培养24小时。24小时培养后,除去培养基,使用PBS清洗细胞之后,添加含有1%Protease Inhibitor Cocktail的RIPA裂解液,经裂解、离心后获得总蛋白提取液,通过BCA法检测提取液中的蛋白浓度;采用SDS-PAGE进行蛋白电泳,之后200mA恒流电转120min将蛋白转印到PVDF(MilliporeSigma IPVH00010)膜上;将PVDF膜置于含有5%的脱脂奶中,室温封闭1h;分别使用Anti-SOS1抗体[12409](CST)进行免疫反应;洗膜后滴加ECL发光液,曝光。使用软件Image J对条带进行灰度分析。每个样品同时检测GAPDH蛋白条带作为内参。根据蛋白条带灰度计算实施例化合物SOS1蛋白降解率,NA代表未测。
化合物在PANC-1细胞中诱导SOS1降解的结果如下所示。
在所有实施例化合物中,化合物1表现出最好的SOS1降解效果,在10μmol/L时对SOS1的降解率>50%。我们选择化合物1进行了SOS1降解活性随时间和剂量的依赖关系研究,如图1中A所示,化合物1对SOS1的降解呈明显的剂量依赖性,DC50为701nM(图1中B)。图2中A为化合物1对SOS1降解的时间依赖性关系,在以3μmol/L的剂量给药24h后,化合物1对SOS1的降解率可以达到70%以上(图2中B)。
实施例28、化合物1对MIA-paca-2的增殖抑制活性
将MIA-paca-2细胞接种在96孔板中,并与连续稀释的化合物1和抑制剂BAY293分别孵育5天。IC50值即半数抑制浓度,通过非线性回归(曲线拟合)使用Graphpad Prism中的可变斜率确定。细胞增殖抑制结果如图3所示,其中显示化合物1表现出对MIA-paca-2细胞的增殖抑制活性,在8.0μmol/L时抑制率达到50%左右。
以上描述是本发明的一般性描述。根据情况或实际需要,可进行形式的变化和等值的替代,虽然本文采用特定的术语,但这些术语意在描述,而不是为了限制的目的。本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围之内。
Claims (10)
1.一种降解SOS1蛋白的化合物,其具有式I所示的结构,
其中:X1、X2各自独立地选自N或C;
Y选自N、S、O、Si或P;
所述R9选自:H;卤素;取代或未取代的直链或支链C1-C6烷基;取代或未取代的直链或支链C1-C6氰基;取代或未取代的直链或支链C1-C6烯基;取代或未取代的直链或支链C1-C6炔基;取代或未取代的直链或支链C1-C6烷氧基;取代或未取代的直链或支链C1-C6仲胺基、叔胺基或季胺基;取代或未取代的直链或支链C1-C6酯基;取代或未取代的直链或支链C1-C6酰胺基;取代或未取代的直链或支链C1-C6酮基;取代或未取代的C1-C10环烷基;取代或未取代的C1-C10杂环基;取代或未取代的C1-C10芳基或杂芳基;
所述G基团选自取代的:
其中:
X选自N或C;
W选自S或O;
m1、m2各自独立的为0-4的整数;
所述R1选自H;-OH;-NH2;卤素;取代或未取代的直链或支链C1-C3烷基;取代或未取代的直链或支链C1-C3烯基;取代或未取代的直链或支链C1-C3炔基;取代或未取代的直链或支链C1-C3羰基;取代或未取代的C1-C10环烷基;取代或未取代的C1-C10杂环基;取代或未取代的C1-C10芳基或杂芳基;
所述连接基团2选自:不存在;或者取代或未取代的直链或具有支链的C1-C12亚烷基;任选的碳链中含有1-4个选自N、S、O、Si或P的杂原子;
所述E3配体选自:
其中:
Q选自CH2、C=O或SO2;
W1、W2、W3各自独立地选自O或S;
m为0-3的整数;
所述R2、R3、R4、R5、R6、R7和R8各自独立的选自:H;-OH;-NH2;卤素;取代或未取代的直链或支链C1-C6烷基;取代或未取代的直链或支链C1-C6氰基;取代或未取代的直链或支链C1-C6烯基;取代或未取代的直链或支链C1-C6炔基;取代或未取代的直链或支链C1-C6烷氧基;取代或未取代的直链或支链C1-C6仲胺基、叔胺基或季胺基;取代或未取代的直链或支链C1-C6酯基;取代或未取代的直链或支链C1-C6酰胺基;取代或未取代的直链或支链C1-C6酮基;取代或未取代的C1-C10环烷基;取代或未取代的C1-C10杂环基;取代或未取代的C1-C10芳基或杂芳基。
2.如权利要求1所述的化合物,其特征在于,其具有式II所示的结构,
其中:
X选自N或C;
W选自S;
m为0-4的整数;
所述R1选自H;-OH;-NH2;卤素;取代或未取代的直链或支链C1-C3烷基;取代或未取代的直链或支链C1-C3烯基;取代或未取代的直链或支链C1-C3炔基;取代或未取代的直链或支链C1-C3羰基;
X1、X2选自N;
Y选自O;
所述R9选自:H;取代或未取代的直链或支链C1-C6烷基;取代或未取代的直链或支链C1-C6氰基;取代或未取代的直链或支链C1-C6烯基;取代或未取代的直链或支链C1-C6炔基;取代或未取代的直链或支链C1-C6烷氧基;取代或未取代的直链或支链C1-C6仲胺基、叔胺基或季胺基;取代或未取代的直链或支链C1-C6酯基;取代或未取代的直链或支链C1-C6酰胺基;取代或未取代的直链或支链C1-C6酮基;
所述连接基团2选自:不存在;或者取代或未取代的直链或具有支链的C1-C12亚烷基;任选的碳链中含有1-4个选自N或O的杂原子;
所述E3配体选自:
其中:
Q选自CH2或C=O;
W1、W2、W3各自独立地选自O;
m3和m4各自为0-3的整数;
所述R2、R3、R4、R5、R6、R7和R8各自独立的选自:H;-OH;-NH2;卤素;取代或未取代的直链或支链C1-C6烷基。
3.如权利要求2所述的化合物,其特征在于,所述化合物具有下述任一结构式:
4.如权利要求1或2或3所述的化合物的立体异构体、溶剂化合物、前药、代谢物、药学上可接受的盐或共晶。
5.含有如权利要求1或2或3所述的化合物,或其立体异构体、溶剂化合物、前药、代谢物、药学上可接受的盐或共晶的药物组合物。
6.如权利要求5所述的药物组合物,还包括药学上可接受的载体。
7.如权利要求1或2或3所述的化合物,或其立体异构体、溶剂化合物、前药、代谢物、药学上可接受的盐或共晶在制备用于治疗或预防与SOS1活性或表达量相关疾病的药物中的应用。
8.如权利要求7所述的应用,其特征在于,所述的化合物或其立体异构体、溶剂化合物、前药、代谢物、药学上可接受的盐或共晶作为SOS1降解剂发挥作用。
9.如权利要求8所述的应用,其特征在于,其用于预防或治疗结肠癌、非小细胞肺癌、胰腺癌、直肠癌、黑色素瘤或多发性骨髓瘤。
10.如权利要求1或2或3所述的化合物的制备方法,其特征在于,其由下述合成路线I与合成路线II、III或IV中的一种组合制备得到所述化合物:
合成路线I:
合成路线II:
合成路线III:
合成路线IV:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311099847.5A CN117143176A (zh) | 2023-08-29 | 2023-08-29 | 降解sos1蛋白的化合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311099847.5A CN117143176A (zh) | 2023-08-29 | 2023-08-29 | 降解sos1蛋白的化合物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117143176A true CN117143176A (zh) | 2023-12-01 |
Family
ID=88886129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311099847.5A Pending CN117143176A (zh) | 2023-08-29 | 2023-08-29 | 降解sos1蛋白的化合物及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117143176A (zh) |
-
2023
- 2023-08-29 CN CN202311099847.5A patent/CN117143176A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6392888B2 (ja) | ヒストン脱アセチル化酵素6阻害剤としての新規化合物およびこれを含む薬剤学的組成物 | |
DK2152258T3 (en) | Derivatives of fluorene, anthracene, xanthene, acridine dibenzosuberone AND DERIVATIVES AND USES | |
JP2022503942A (ja) | イソインドリン化合物、その調製方法、医薬組成物および使用 | |
KR101335746B1 (ko) | 이치환된 프탈라진 헷지호그 경로 길항제 | |
CN101925573A (zh) | 新型的n-(2-氨基-苯基)-酰胺衍生物 | |
EA023649B1 (ru) | ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ТЕТРАГИДРОИЗОХИНОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА XIa | |
AU2007233732B2 (en) | N-hydroxy-3-(4-{3-phenyl-s-oxo-propenyl}-phenyl)-acrylamide derivatives and related compounds as histone deacetylase inhibitors for the treatment of cancer | |
JP6219720B2 (ja) | 新規な化合物、その製造方法および用途 | |
CN110386927B (zh) | 组蛋白乙酰转移酶(hat)抑制剂及其用途 | |
JP6876875B2 (ja) | Prc2介在の疾患を治療するためのトリアゾロピリミジン、トリアゾロピリジン化合物及びその組成物 | |
EP2443092A1 (en) | Bicyclic and tricyclic compounds as kat ii inhibitors | |
EP4269392A1 (en) | Tetrahydroquinoline derivative and medicinal use thereof | |
WO2020103878A1 (zh) | Er蛋白调节剂及其应用 | |
MX2014012992A (es) | Derivado de quinazolindiona. | |
EP3760633B1 (en) | Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof | |
EP2197854B1 (en) | A new class of histone deacetylase inhibitors | |
KR102537615B1 (ko) | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 | |
CN111233661B (zh) | 靶向泛素化降解ERRα蛋白的化合物及其药用组合物和应用 | |
CA2730071A1 (fr) | Derives anticancereux, leur preparation et leur application en therapeutique | |
WO2017018475A1 (ja) | 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途 | |
CN117143176A (zh) | 降解sos1蛋白的化合物及其用途 | |
CN117242061A (zh) | 用于治疗艰难梭菌的二氮杂卓衍生物 | |
JP2009523747A (ja) | α7ニコチン性アセチルコリン受容体のモジュレーターおよびその治療上の使用 | |
CN117143175A (zh) | 靶向sos1蛋白泛素化调节的化合物及其制备方法和应用 | |
WO2016057753A1 (en) | Substituted pyrimidines as inhibitors of hif prolyl hydroxylase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |